- Anisometropic amblyopia—Vision in one eye differs from the other. This is often caused by a large difference in eyeglass prescription. The difference may be caused by 1 eye being more nearsighted or farsighted than the other, or by large differences in astigmatism .
- Strabismic amblyopia— Visible misalignment (crossing) of one eye.
|Copyright © Nucleus Medical Media, Inc.|
- Crossed eyes
A large difference in sight between the 2 eyes that may be:
- Detected by a large difference in eyeglass prescription
- Visual blockage such as a cataract, droopy eyelid, or corneal scarring
- A droopy (the inability to fully-open) eyelid that blocks the pupil
- Blurry vision
- Excessive squinting or closing of the eyes
- Repeatedly closing of one eye in bright sunlight
- Crossing of one eye, generally the eye that is less used will excessively turn toward the nose
- Visual acuity assessment testing (VAT)—to assess distant vision
- Cycloplegic refraction test—to assess how the eyeball displays and receives images produced by the lens of the eye
- Retinoscopy—to determine a preverbal child’s eyeglass prescription
- Prisms—to determine the amount of crossing between the 2 eyes
Eye Smart—American Ophthalmology http://www.geteyesmart.org
National Eye Institute (NEI) http://www.nei.nih.gov
Canadian Ophthalmological Society http://www.cos-sco.ca
The Canadian National Institute for the Blind http://www.cnib.ca
Amblyopia. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated August 13, 2012. Accessed June 30, 2013.
Bhola R, Keech RV, et al. Recurrence of amblyopia after occlusion therapy. Ophthalmology. 2006;113(11):2097-2100.
Campos, EC, Schiavi, et al. Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes Arch Clin Exp Ophthalmol.1995;233(5):307-312.
Fleck BW. Amblyopia therapy. Br J Ophthalmol. 2003;87(3):255-266.
Flynn JT, Schiffman J, et al. The therapy of amblyopia: An analysis of the results of amblyopia therapy utilizing the pooled data of published studies. Trans Am Ophthalmol Soc. 1998;96: 431-450; discussion 450-453.
Holmes JM, Beck RW, et al. Pediatric Eye Disease Investigator Group. Impact of patching and atropine treatment on the child and family in the amblyopia treatment study. Arch Ophthalmol. 2003;121(11):1625-1632.
Kushner BJ. Atropine vs. patching for the treatment of moderate amblyopia in children. Arch Ophthalmol. 2002;120(3):387-388.
LaRoche GR. Amblyopia: Detection, prevention, and rehabilitation. Curr Opin Ophthalmol. 2001;12(5):363-367.
Leguire LE, Rogers GL, Walson PD, Bremer DL. Occlusion and levodopa-carbidopa treatment for childhood amblyopia. J AAPOS.1998;2(5).
Loudon SE, Simonsz HJ. The history of the treatment of amblyopia. Strabismus. 2005;13(2):93-106.
Ohlsson J, Baumann M, et al. Long term visual outcome in amblyopia treatment. Br J Ophthalmol. 2002; 86(10):1148-51.
Pediatric Eye Disease Investigator Group. A comparison of atropine and patching treatments for moderate amblyopia by patient age, cause of amblyopia, depth of amblyopia, and other factors. Ophthalmology . 2003;110(8):1632-7; discussion 1637-8.
Powell C, Porooshani H, et al. Screening for amblyopia in childhood. Cochrane Database Syst Rev. 2005;(3):CD005020.
Quinn GE, Beck RW, et al. Pediatric Eye Disease Investigator Group. Recent advances in the treatment of amblyopia. Pediatrics. 2004;113 (6):1800-1802.
Sakatani K, Jabbur NS, et al. Improvement in best corrected visual acuity in amblyopic adult eyes after laser in situ keratomileusis. J Cataract Refract Surg. 2004;30(12):2517-2521.
Simons K. Amblyopia characterization, treatment, and prophylaxis. Surv Ophthalmol. 2005;50(2):123-166.
5/28/2010 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed: Pediatric Eye Disease Investigator Group Writing Committee, Rutstein RP, Quinn GE, et al. A randomized trial comparing Bangerter filters and patching for the treatment of moderate amblyopia in children. Ophthalmology. 2010;117(5):998-1004.
2/4/2011 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed: US Preventive Services Task Force. Vision screening for children 1 to 5 years of age: US Preventive Services Task Force recommendation statement. Pediatrics. 2011;127(2):340-346.
- Reviewer: Michael Woods, MD
- Review Date: 12/2014 -
- Update Date: 12/20/2014 -
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
Copyright © EBSCO Publishing
All rights reserved.